In vitro activity of the novel ketolide HMR 3647 and comparative oral antibiotics against Canadian respiratory tract isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

被引:32
作者
Hoban, DJ
Zhanel, GG
Karlowsky, JA
机构
[1] Hlth Sci Ctr, Dept Clin Microbiol, Winnipeg, MB R3A 1R9, Canada
[2] Hlth Sci Ctr, Dept Med, Winnipeg, MB R3A 1R9, Canada
[3] Univ Manitoba, Fac Med, Dept Med Microbiol, Winnipeg, MB, Canada
[4] Univ Manitoba, Fac Pharm, Winnipeg, MB R3T 2N2, Canada
关键词
D O I
10.1016/S0732-8893(99)00053-X
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The in vitro activities of HMR 3647, erythromycin A, clarithromycin, azithromycin, roxithromycin, penicillin G, ampicillin, cefuroxime, trimethoprim/sulfamethoxazole, tetracycline, ciprofloxacin, and levofloxacin were determined for 1179 Streptococcus pneumoniae, 1438 Haemophilus influenzae, and 428 Moraxella catarrhalis isolated from respiratory tract specimens by 18 medical centers across Canada during 1997-1998. On a per weight basis, HMR 3647 was the most active agent tested against S, pneumoniae with MIC(90)s of less than or equal to 0.12 mu g/mL for both penicillin susceptible and penicillin intermediate isolates and 0.25 mu g/mL for penicillin-resistant isolates. HMR 3647 was also highly active against M. catarrhalis (MIC(90), less than or equal to 0.12 mu g/mL), but less active against H. influenzae (MIC(90), 4 mu g/mL). (C) 1999 Elsevier Science Inc.
引用
收藏
页码:37 / 44
页数:8
相关论文
共 11 条
[1]  
[Anonymous], 1999, M100S9 NAT COMM CLIN
[2]   In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae [J].
Barry, AL ;
Fuchs, PC ;
Brown, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (08) :2138-2140
[3]   Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin) [J].
Barry, AL ;
Fuchs, PC ;
Brown, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) :945-946
[4]   In-vitro activity of ketolides against mycoplasmas [J].
Bebear, CM ;
Renaudin, H ;
Aydin, MD ;
Chantot, JF ;
Bebear, C .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (05) :669-670
[5]   Ketolides lack inducibility properties of MLSB resistance phenotype [J].
Bonnefoy, A ;
Girard, AM ;
Agouridas, C ;
Chantot, JF .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) :85-90
[6]  
Bryskier A, 1997, INFEC DIS T, V21, P39
[7]   Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study [J].
Doern, GV ;
Brueggemann, A ;
Holley, HP ;
Rauch, AM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) :1208-1213
[8]   Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against Gram-positive cocci of known erythromycin susceptibility status [J].
Hamilton-Miller, JMT ;
Shah, S .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (06) :649-653
[9]   Antimicrobial activity of RU-66647, a new ketolide [J].
Jones, RN ;
Biedenbach, DJ .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 27 (1-2) :7-12
[10]  
*NAT COMM CLIN LAB, 1997, M7A4 NAT COMM CLIN L